Gastrointestinal Stromal Tumor (GIST)

KIT/PDGFRA-driven mesenchymal tumor of the GI tract — imatinib as the paradigm-defining targeted therapy and the molecular genotyping framework that guides every treatment decision

Key Points

• GIST is the most common mesenchymal tumor of the GI tract (~5,000–6,000 new cases/year in the United States), arising from the interstitial cells of Cajal (ICC) or their precursors; the stomach (~60%) and small intestine (~30%) are the most common primary sites.
• Activating mutations in KIT (~75%) or PDGFRA (~10%) are the molecular hallmarks of GIST; KIT/PDGFRA genotype is the single most important determinant of prognosis and treatment selection — molecular testing of all GISTs is mandatory.
• Imatinib (a KIT/PDGFRA/ABL tyrosine kinase inhibitor) transformed metastatic GIST from a uniformly fatal disease with median OS <1 year to a chronic disease with median OS >5 years; it is the prototype for targeted therapy in oncology.
• PDGFRA D842V mutations (~6% of all GIST) are imatinib-resistant; avapritinib is specifically approved for PDGFRA D842V–mutant GIST with response rates >85% — mutation testing before starting imatinib is essential.
• KIT exon 9 mutations (~10%) require imatinib 800 mg/day (double the standard dose) or upfront sunitinib for optimal outcomes; KIT/PDGFRA wild-type GIST (10–15%) requires evaluation for SDH deficiency, NF1, BRAF V600E, and fusions (NTRK, FGFR1, ALK).
• Adjuvant imatinib for 3 years (vs. 1 year) significantly improves relapse-free and overall survival in high-risk resected GIST (SSGXVIII/AIO trial); risk stratification using the modified NIH/Joensuu criteria guides adjuvant therapy duration.

Epidemiology, Cell of Origin, and Molecular Classification

GIST arises from the interstitial cells of Cajal (ICC) — the pacemaker cells of the GI tract that coordinate peristalsis — or from a shared ICC/smooth muscle progenitor cell. It accounts for ~1–2% of all GI malignancies but is the most common mesenchymal (non-epithelial) GI tumor. Median age at diagnosis is 60–65 years; slight male predominance. GISTs can occur anywhere in the GI tract but most commonly arise in the stomach (60%), small intestine (30%), rectum (5%), esophagus (<5%), and mesentery/omentum (5% — extra-GI GIST). **Molecular Classification — the genotype-treatment framework:**…

Pathology and Diagnosis

**Histopathology:** GIST morphology falls into three patterns — spindle cell (~70%), epithelioid (~20%), and mixed (~10%). Spindle cell GISTs have elongated, blunt-ended nuclei with eosinophilic fibrillary cytoplasm arranged in fascicles; epithelioid GISTs have rounded cells with clear or eosinophilic cytoplasm resembling carcinoma or lymphoma. The morphology alone cannot predict genotype, though epithelioid morphology raises suspicion for PDGFRA mutation. **Immunohistochemistry:** IHC is central to confirming the diagnosis and guiding molecular testing: - **KIT (CD117)+:** ~95% of GISTs;…

Staging and Risk Stratification

Unlike carcinomas, GIST is not primarily staged by TNM; **risk stratification** for recurrence after complete resection guides clinical decision-making. **Modified NIH/Joensuu Criteria (most widely used):** Four parameters define risk category: 1. **Tumor size** (longest diameter) 2. **Mitotic rate** (per 50 high-power fields, HPF) 3. **Primary tumor location** (gastric vs. non-gastric — gastric GISTs behave more favorably than small intestinal/rectal at equivalent size and mitotic rate) 4. **Tumor rupture** (intraoperative or spontaneous — automatically high risk regardless of other…

Treatment — Localized Disease

**Surgery — the Cornerstone of Curative-Intent Treatment:** Complete gross resection (R0) with an intact pseudocapsule is the goal; wide surgical margins beyond the pseudocapsule do not improve outcomes (unlike sarcomas). Lymph node dissection is not indicated (lymphatic spread is rare in GIST). Laparoscopic resection is appropriate for gastric GISTs ≤5 cm at experienced centers. For rectal GISTs, neoadjuvant imatinib to shrink the tumor before sphincter-sparing resection is preferred. Tumor rupture must be avoided — rupture seeds the peritoneal cavity and confers a high-risk designation…

Treatment — Advanced and Metastatic Disease

**First-Line: Imatinib 400 mg/day (KIT exon 11 and PDGFRA non-D842V):** Imatinib 400 mg/day achieves disease control (CR + PR + SD) in ~85% of KIT exon 11–mutant metastatic GIST; median PFS ~20–24 months; median OS >5 years. The landmark ACOSOG Z9001 and European EORTC trials established imatinib as the standard for unresectable/metastatic GIST. Imatinib is continued indefinitely until progression or intolerance — stopping imatinib in responding patients leads to rapid progression in >90%. **KIT Exon 9 Mutation — Imatinib 800 mg/day:** KIT exon 9–mutant GIST requires imatinib 800 mg/day (two…

Resistance Mechanisms and Monitoring

**Primary Resistance:** Defined as progression on first-line imatinib within 6 months. Causes: - PDGFRA D842V (imatinib steric exclusion) — use avapritinib - SDH-deficient GIST, NF1-GIST, BRAF V600E — lack KIT/PDGFRA dependence - Rare primary KIT exon 11 mutations at specific codons **Secondary Resistance:** Defined as progression after initial response to imatinib. The dominant mechanism is acquisition of secondary mutations in KIT kinase domain exons 13, 14, 17, or 18 — a subclonal event within heterogeneous tumor cell populations. Because multiple resistance clones arise simultaneously…